XCUR_OUT_1 [2025-04-24 04:35:02 -0400] 5204 Bytes | 1480 tokens | Cum: 1480 tkns (18.50% of 8k)
==========================================================================

Listen up, partner—it's 4:35 AM on Thu Apr 24, 2025, and I’m revved up about Exicure (XCUR), climbing from $8.44 to $10.64. This stock is buzzing big-time—do we have a hidden gem, or a flash in the pan? Help me sift through the data!

--- COMPANY PROFILE ---
Company: Exicure (XCUR)
IPO: 2018-05-09 (6 Years Ago)
Market Cap: $72,970,255
Shares Outstanding: 6,320,000
Industry: PHARMACEUTICAL PREPARATIONS
Exchange: XNAS
Description: Exicure Inc is an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. It operates in a single segment which is Biotechnology.

Here’s a list of headlines for Exicure:

Apr-22-25 09:21AM - Why Exicure Inc. (XCUR) Soared on Monday
Apr-14-25 06:11PM - Exicure, Inc. (Nasdaq: XCUR) Nears Completion of Phase 2 Study of GPC-100 in Multiple Myeloma
Apr-11-25 07:42PM - Exicure, Inc. (Nasdaq: XCUR) Announces Their Next Step in Planning for a New Clinical Trial in Acute Myeloid Leukemia (AML)
Mar-18-25 04:01PM - Exicure, Inc. Reports Full Year 2024 Financial Results
Mar-13-25 04:08PM - Exicure, Inc. (Nasdaq: XCUR) Announces Issuance of New Patent in Australia
Jan-23-25 12:17AM - CORRECTING and REPLACING Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics Inc.
Jan-22-25 04:01PM - Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics Inc.
Dec-26-24 08:08PM - Exicure, Inc. Partners with GPCR Therapeutics to Fuel New Growth in Biotech
Dec-21-24 01:48PM - CORRECTING and REPLACING Exicure, Inc. Announces Shareholders Approve the $8.7 Million Equity Financing and Reports Executive Management and Board Changes
Dec-20-24 04:42PM - Exicure, Inc. Announces Shareholders Approve the $8.7 Million Equity Financing and Reports Executive Management and Board Changes
Nov-14-24 04:01PM - Exicure, Inc. Enters into Purchase Agreements for $1.3 Million and $8.7 Million Equity Financing and Reports Third Quarter 2024 Financial Results
Sep-18-24 04:01PM - Exicure, Inc. Receives Extension from Nasdaq Hearings Panel
Sep-09-24 06:53PM - Exicure, Inc. Announces Proposed Settlement of Securities Class Action Litigation
Aug-26-24 09:08AM - Exicure, Inc. Announces 1-for-5 Reverse Stock Split
Aug-19-24 10:31AM - Exicure, Inc. Announces Additional Adjournment of Special Meeting and Information for Reconvened Special Meeting
Aug-15-24 10:31AM - Exicure, Inc. Announces Adjournment of Special Meeting and Information for Reconvened Special Meeting
Aug-13-24 04:01PM - Exicure, Inc. Reports Second Quarter 2024 Financial Results
Aug-08-24 04:27PM - Exicure, Inc. Recruits Head of Corporate Development and Bioinformatics
Aug-02-24 07:34AM - Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Aug-01-24 04:01PM - Exicure, Inc. Receives Positive Listing Determination from Nasdaq
Jul-26-24 07:36AM - Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Jun-17-24 09:53PM - XCUR Stock Earnings: Exicure Reported Results for Q1 2024

Here's another list of headlines with menu handles.
I will deliver the full text of the following stories when you say their handle.
Just say, for example, B1, B2, etc.

B1 - 2024-02-06T18:17:47Z - Why FMC Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
B2 - 2024-02-06T13:16:16Z - Why Palantir Technologies Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket
B3 - 2024-01-11T12:51:27Z - Why Richardson Electronics Shares Are Trading Lower By 13%; Here Are 20 Stocks Moving Premarket
B4 - 2024-01-10T18:06:18Z - Why WD-40 Shares Are Trading Higher By Over 17%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
B5 - 2024-01-10T13:02:59Z - Why Aehr Test Systems Shares Are Trading Lower By 15%; Here Are 20 Stocks Moving Premarket
B6 - 2023-12-12T13:00:08Z - Why Icosavax Shares Are Trading Higher By Around 45%; Here Are 20 Stocks Moving Premarket

==============
-> THE ROLE FOR AI:
==============

1) You are the **AI analyst-investigator**, and this interaction represents a full **due diligence session** for Exicure (XCUR).
Due diligence includes financial data, insider trading, relevant news, and any SEC filings — and may extend beyond classic fundamentals.
Your task is to identify whether this stock has momentum and potential.

2) I am **ScanScor**, a unified report generator that archives this session as part of our real-time diligence record.

3) You will request information by referencing documents by their code.

4) As the analysis proceeds, your are encouraged to review documents until you feel confident in your judgment.
After seeing 3 sets of news articles, SEC docs, and financials, you'll be prompted to return some data pairs.

5) News articles, SEC filings, and key metrics will be revealed in subsequent prompts.

Stay focused. Gather evidence. Continue until your conclusions are clear.
Restrict all your responses to just 3 tokens until the summary and data pairs at the end.

NEXT: Request a document with its reference code(s), such as:
- `B1`, `B2`, `B3`, etc.
- To load a new set of information and menu options, reply with: `NEX`

XCUR_OUT_3 [2025-04-24 04:35:03 -0400] 880 Bytes | 279 tokens | Cum: 1761 tkns (22.01% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-22T13:28:43Z - Why Exicure Inc. (XCUR) Soared on Monday...
A2 - 2025-04-22T13:21:16Z - Why Exicure Inc. (XCUR) Soared on Monday...
A3 - 2025-04-21T17:05:41Z - 12 Health Care Stocks Moving In Monday's Intraday Session - Annovis Bio (NYSE:ANVS), Adagio Medical ...
A4 - 2025-04-20T07:08:28Z - Exicure, Inc. (NASDAQ:XCUR) Sees Large Drop in Short Interest...
A5 - 2025-04-17T21:05:38Z - 12 Health Care Stocks Moving In Thursday's After-Market Session - Adagio Medical Holdings (NASDAQ:AD...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

XCUR_OUT_5 [2025-04-24 04:35:04 -0400] 1181 Bytes | 311 tokens | Cum: 2074 tkns (25.92% of 8k)
==========================================================================

Showing A1 (chunk 1 of 4): A1:
**Why Exicure Inc. (XCUR) Soared on Monday**Date: 2025-04-22Source: {'uri': 'finance.yahoo.com', 'dataType': 'news', 'title': 'Yahoo! Finance'}URL: https://finance.yahoo.com/news/why-exicure-inc-xcur-soared-132116901.htmlWe recently compiled a list of the 10 Micro-, Small-Cap Companies Lead Monday's Charge. In this article, we are going to take a look at where Exicure Inc. (NASDAQ:XCUR) stands against the other stocks.

The stock market ended the first trading day of the week in the negative territory, with all major indices recording hefty losses, as investors continued to digest the impact of President Donald Trump's tariff policies and his criticism of the Federal Reserve.

The tech-heavy Nasdaq fell the hardest among the major indices, down 2.55 percent, followed by the Dow Jones at 2.48 percent, and the S&P 500 at 2.36 percent.

Meanwhile, 10 companies bucked a broader market bl

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

XCUR_OUT_7 [2025-04-24 04:35:05 -0400] 1181 Bytes | 295 tokens | Cum: 2371 tkns (29.64% of 8k)
==========================================================================

Showing A1 (chunk 2 of 4): oodbath, recording strong gains during the day. We have listed the 10 top-performing companies, dominated by micro- to small-cap stocks, and detailed the reasons behind their gains.

To come up with the list, we considered only the stocks with less than $1 billion in market capitalization.

A scientist examining a vial of drugs in a lab, representing the biotechnology company's research.

Exicure Inc. (NASDAQ:XCUR) snapped a three-day losing streak on Monday, surging 27.68 percent to close at $11.30 apiece as investors resorted to bargain-hunting to take advantage of its cheap valuations.

Additionally, investors digested news that Exicure Inc. (NASDAQ:XCUR), through its subsidiary, GPCR Therapeutics USA, was nearing completion of the phase 2 study of GPC-100 in Multiple Myeloma. This followed the successful dosing of the 19th patient to evaluate the efficacy of GPC-100 (burixafor) in mo

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

XCUR_OUT_9 [2025-04-24 04:35:05 -0400] 1181 Bytes | 257 tokens | Cum: 2630 tkns (32.88% of 8k)
==========================================================================

Showing A1 (chunk 3 of 4): bilizing stem cells in multiple myeloma (MM) patients undergoing autologous stem cell transplant.

"Preliminary results are encouraging, with 100 percent of patients achieving the primary endpoint of successful CD34+ stem cell mobilization, including patients previously treated with daratumumab," XCUR said.

The trial is expected to finish patient recruitment by the end of the month.

Exicure Inc. (NASDAQ:XCUR) has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. Following its restructuring and suspension of clinical and development activities, the company said it is now exploring strategic alternatives to maximize stockholder value.

Overall XCUR ranks 10th on our list of Monday's top performers. While we acknowledge the potential of XCUR as an investment, our conviction lies in the

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

XCUR_OUT_11 [2025-04-24 04:35:06 -0400] 671 Bytes | 165 tokens | Cum: 2797 tkns (34.96% of 8k)
==========================================================================

Showing A1 (chunk 4 of 4): belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than XCUR but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock.

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

XCUR_OUT_13 [2025-04-24 04:35:07 -0400] 1090 Bytes | 282 tokens | Cum: 3081 tkns (38.51% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-03-18 10-K Item 7. Mgts Discussion and Analysis of Fin Cond and Results of Oper.

You should read the following discussion and analysis of our financial condition and results of operations together with our CONS financial statements and the related notes an...

S2 - 2025-03-18 8-K Item 2.02 Results of Oper and Fin Cond.

On March 18, 2025, Exicure, Inc. (the Company) issued a press release announcing its financial and operational results for the fiscal year ended December 31, 2024. A copy of the press release is being furnished as Exhibit...

S4 - 2025-02-21 8-K Item 1.01 Entry Into a Material Definitive Agrmt

Common Stock Purchase Agrmt

On February 14, 2024, Exicure, Inc. (the Company) entered into a Common Stock Purchase Agrmt with Shin Chang Partners and RMS0718 Co., Ltd. (the Purchasers), pursuant to which the Company...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

XCUR_OUT_15 [2025-04-24 04:35:08 -0400] 1181 Bytes | 243 tokens | Cum: 3326 tkns (41.58% of 8k)
==========================================================================

Showing S1 (chunk 1 of 6): S1:
Item 7. Managements Discussion and Analysis of Financial Condition and Results of Operations.

You should read the following discussion and analysis of our financial condition and results of operations together with our consolidated financial statements and the related notes and other financial information included elsewhere in this Annual Report on Form 10-K. Some of the information contained in this discussion and analysis or set forth elsewhere in this Annual Report on Form 10-K, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties as described under the heading Cautionary Note Regarding Forward-Looking Statements elsewhere in this Annual Report on Form 10-K. You should review the disclosure under the heading Risk Factors in this Annual Report on Form 10-K for a discussion of import

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

XCUR_OUT_17 [2025-04-24 04:35:09 -0400] 1181 Bytes | 246 tokens | Cum: 3574 tkns (44.67% of 8k)
==========================================================================

Showing S1 (chunk 2 of 6): ant factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.

Overview

Historically, we have been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. In September 2022, we announced a significant reduction in force, suspension of preclinical activities and halting of all research and development, and that we were exploring strategic alternatives to maximize stockholder value. In February 2024, we received an upfront payment of $500,000 from a licensing agreement for patents related to one of our historical drug candidates, and received a small, one-time payment and an entitlement to only modest royalties on future sales of the licensed technology that we do not believe will

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

XCUR_OUT_19 [2025-04-24 04:35:09 -0400] 1181 Bytes | 241 tokens | Cum: 3817 tkns (47.71% of 8k)
==========================================================================

Showing S1 (chunk 3 of 6): be material. In the second quarter, we recognized other income of $637,000 from the sale of our samples related to the licensed product. In the third quarter, we sold our historical biotechnology intellectual property and other assets (including the licensing agreement described above) pursuant to the purchase agreement and recognized other income of $1,500,000. We continue to engage in a broader exploration of strategic alternatives. This effort involves exploring growth through transactions with potential partners that see opportunity in joining an existing, publicly-traded organization.

Following the purchase agreement, any value we may generate from our historical biotechnology intellectual property and other assets will be primarily through royalties and license fees that we may receive in the future under the purchase agreement. However, whether we receive any royalties or licen

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

XCUR_OUT_21 [2025-04-24 04:35:10 -0400] 1181 Bytes | 262 tokens | Cum: 4081 tkns (51.01% of 8k)
==========================================================================

Showing S1 (chunk 4 of 6): ses fees, and the amounts and timing thereof, are uncertain and out of our control.

While the foregoing efforts are continuing, with respect to our historical assets, we do not expect they will generate significant value for stockholders. Therefore, we are engaging in a broader exploration of strategic alternatives. We obtained significant financing late in 2024 in order to continue operations and our exploration of strategic alternatives and consummate any transactions that we may identify.

Operating, financing, and cash flow considerations

Since our inception in 2011, we have primarily funded our operations through sales of our securities, loans and collaborations. Effective as of November 12, 2024, we entered into the Initial Common Stock Purchase Agreement with HiTron, pursuant to which we agreed to issue and sell to HiTron 433,333 shares of our common stock, par value $0.0001

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

XCUR_OUT_23 [2025-04-24 04:35:11 -0400] 1181 Bytes | 303 tokens | Cum: 4386 tkns (54.83% of 8k)
==========================================================================

Showing S1 (chunk 5 of 6): per share (the Common Stock), for an aggregate purchase price of $1.3 million, at a purchase price per share of $3.00. On November 13, 2024, we entered into the Subsequent Common Stock Purchase Agreement, pursuant to which we agreed to sell and issue to HiTron 2,900,000 additional shares of Common Stock for an aggregate purchase price of $8.7 million, at a purchase price per share of $3.00. The issuance of such shares under the Subsequent Common Stock Purchase Agreement closed on December 24, 2024.

On December 9, 2024, we entered into a common stock purchase agreement (the SangSang Purchase Agreement) with SangSangIn Investment Securities Co., Ltd. (SangSang), pursuant to which we agreed to issue and sell to SangSang 433,332 shares of our Common Stock, for an aggregate purchase price of approximately $2.0 million, at a purchase price per share of $4.61. The transactions under the SangS

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

XCUR_OUT_25 [2025-04-24 04:35:11 -0400] 790 Bytes | 187 tokens | Cum: 4575 tkns (57.19% of 8k)
==========================================================================

Showing S1 (chunk 6 of 6): ang Purchase Agreement closed on December 24, 2024.

As of December 31, 2024, our cash and cash equivalents cash were approximately $12.5 million. Our current liquidity may not be sufficient to fund operations for the next 12 months. As a result, there is substantial doubt about

our ability to continue as a going concern. Additional financing will be needed to fund our ongoing operations and exploration of strategic alternatives and pursue any alternatives that we identify. If we are unable to ra...

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

XCUR_OUT_27 [2025-04-24 04:35:19 -0400] 6037 Bytes | 1598 tokens | Cum: 6175 tkns (77.19% of 8k)
==========================================================================

This is our set of metrics for Exicure.
Please analyze the numbers.

+--------------------+------------------------+-------------------------+------------------------+
| Volume: 27,051 | Perf Month: -17.02% | Option/Short: No / Yes | Sales Y/Y TTM: -97.70% |
+--------------------+------------------------+-------------------------+------------------------+
| Avg Volume: 33.47K | Perf Quarter: 8.58% | Short Float: 4.18% | ROE: -197.92% |
+--------------------+------------------------+-------------------------+------------------------+
| Rel Volume: 0.59 | Index: - | Short Ratio: 1.02 | ROI: -80.94% |
+--------------------+------------------------+-------------------------+------------------------+
| RSI (14): 47.44 | Market Cap: 71.14M | Short Interest: 0.03M | Sales Surprise: - |
+--------------------+------------------------+-------------------------+------------------------+
| ATR (14): 1.45 | Shs Outstand: 6.03M | Beta: 3.85 | EPS Surprise: - |
+--------------------+------------------------+-------------------------+------------------------+
| SMA20: -7.28% | Shs Float: 0.82M | Sales Q/Q: - | P/E: - |
+--------------------+------------------------+-------------------------+------------------------+
| SMA50: -0.75% | Inst Own: 0.41% | Sales past 5Y: 1409.42% | Earnings: Mar 18 AMC |
+--------------------+------------------------+-------------------------+------------------------+
| SMA200: 37.84% | Insider Own: 86.98% | Employees: 7 | |
+--------------------+------------------------+-------------------------+------------------------+
| Perf Week: -3.76% | Insider Trans: 111.74% | Debt/Eq: 0.88 | |
+--------------------+------------------------+-------------------------+------------------------+

The next section covers any insider trading by Exicure officers or majority shareholders (if available).

Inside Trans: EXICURE, INC. (XCUR) by Miller Josh (Chief Accounting Officer) on 2025-02-16
- Common Stock: 9 shares at $10.03 (D)

No transactions recorded.

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 500000, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -9701000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 11.26
Average Volume: 26728.67
30-Day High: 14
30-Day Low: 8.44

[Detailed Financials: TTM 2024]
- Total Assets: $15,056,000.00
- Total Liabilities: $8,284,000.00
- Total Equity: $6,772,000.00
- Current Assets: $13,673,000.00
- Current Liabilities: $3,071,000.00

[Income Statement: TTM 2024]
- Revenue: $500,000.00
- Net Income: $-9,701,000.00
- Gross Profit: N/A
- Operating Income: $-12,232,000.00
- Earnings Per Share (EPS): -4.75

[Cash Flow Statement: TTM 2024]
- Net Cash Flow: $0.00

[Detailed Financials: FY 2024]
- Total Assets: $15,056,000.00
- Total Liabilities: $8,284,000.00
- Total Equity: $6,772,000.00
- Current Assets: $13,673,000.00
- Current Liabilities: $3,071,000.00

[Income Statement: FY 2024]
- Revenue: $500,000.00
- Net Income: $-9,701,000.00
- Gross Profit: N/A
- Operating Income: $-12,232,000.00
- Earnings Per Share (EPS): -4.75

[Cash Flow Statement: FY 2024]
- Net Cash Flow: $0.00
==== END OF FINANCIAL REPORT ====

You are now requested to write a summary analysis of Exicure (XCUR).

Please complete the report using the exact format:
FIELD[value]

1) BRIEF_SUMMARY[]
One well-worded paragraph summarizing your findings about Exicure.

2) MARKET_SCORE[]
This conversation was initiated because XCUR is currently experiencing upward price and volume movement.
Estimate a number between 1–100 based on the likelihood of a continued upward price move for XCUR.
Weigh relevant data — news, filings, fundamentals, and metrics — and assign appropriate weight.

3) PRICE_TARGET[]
Suggest a price, based on all prior evidence and past price behavior, XCUR could reach in the current or upcoming trading sessions (1–5 days).
For example, if you expect XCUR to increase 50% from its current price of $0.00, say: PRICE_TARGET[0.0]

4) AI_RPT_HEADLINE[]
Write a thought-provoking 8–12 word headline summarizing this report.

5) SQUEEZE_POTENTIAL[]
Give a score from 1 to 100 representing the potential for this stock to become an active short squeeze play.
Be honest and unbiased. Consider short interest/float, price movement, volume, news strength, and volatility potential.

6) TAGS[]
List 3–6 comma-separated tags (e.g., biotech, earnings beat, squeeze setup)

7) STOCK_TYPE[]
Choose the most accurate classification: growth, value, turnaround, hype, squeeze, dividend, speculative, or other.

8) PRIMARY_CATALYST[]
e.g., earnings report, FDA approval, partnership, etc.

9) SENTIMENT[]
bullish, bearish, neutral, or mixed

10) IMPROVEMENT_SUGGESTION[]
If you believe some key info was missing, state what would have significantly improved your analysis of Exicure.

11) ETHICAL_RATING[]
Rate Exicure’s alignment with long-term shareholder interests, using a letter grade from A (high alignment) to F (low alignment).
Base this on actions such as insider buying/selling, share dilution, follow-through on public statements, and compensation practices.

12) UPCOMING_CATALYST[]
Specify any upcoming events you expect would be a catalyst affecting the share-price of Exicure.
Provide any reasons you can use to support it.

Return only: FIELD[value] for each of the above 12 questions.
Respond with all data pairs. Take your best guess if you have to, but don't leave blank items.
Do not explain your answers. Return only the required fields in the exact format shown.

Finally, thank you for participating!

XCUR_IN_29 [2025-04-24 04:35:19 -0400] 126 Bytes | 29 tokens | Cum: 6453 tkns (80.66% of 8k)
==========================================================================

====================================
[2025-04-24 04:35:19] # Analysis Completed
Elapsed Time: 19.37 seconds